Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...

(RTTNews) - GE Healthcare said Monday that the U.S. Food and Drug Administration approved Clariscan, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE Healthcare portfolio ...

Bayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication for Gadavist (gadobutrol) injection for intravenous use with MRI of the breast to assess the ...

Expanded use of Gadavist is specific to detecting and visualizing areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in pediatric patients under the age ...

Woburn, MA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ferabright TM (ferumoxytol injection), the ...

PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...

We are looking for volunteers to undergo magnetic resonance imaging (MRI) scans of the brain, with gadolinium-based contrast agent injection. Participants will be paid $80. The total scan duration is ...

MRI scans are powerful diagnostic tools. In the 1990s they became commonly used, and contrast agents that contain the rare earth metal gadolinium were created to enhance the sharpness of the images.

A chemical injected before MRI scans to help create sharper images may cause some patients to experience a potentially deadly complication in rare cases, a new study suggests. Researchers from the ...

CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...